Yungjin Pharm. Co., Ltd. (003520.KS)
KRW 1989.0
(-2.02%)
KRW 1989.0
(-2.02%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 226.6 Billion KRW | 11.58% |
| 2022 | 203.08 Billion KRW | 4.63% |
| 2021 | 194.09 Billion KRW | 3.19% |
| 2020 | 188.1 Billion KRW | -6.16% |
| 2019 | 200.44 Billion KRW | 2.21% |
| 2018 | 196.11 Billion KRW | -3.79% |
| 2017 | 203.84 Billion KRW | 2.25% |
| 2016 | 199.35 Billion KRW | 2.92% |
| 2015 | 193.69 Billion KRW | 8.23% |
| 2014 | 178.96 Billion KRW | 5.69% |
| 2013 | 169.33 Billion KRW | 4.56% |
| 2012 | 161.95 Billion KRW | 2.64% |
| 2011 | 157.78 Billion KRW | 6.77% |
| 2010 | 147.78 Billion KRW | 7.57% |
| 2009 | 137.38 Billion KRW | 4.13% |
| 2008 | 131.93 Billion KRW | 22.04% |
| 2007 | 108.11 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 235.65 Billion KRW | 0.79% |
| 2024 Q1 | 233.81 Billion KRW | 3.18% |
| 2023 Q1 | 207.38 Billion KRW | 2.12% |
| 2023 Q3 | 219.98 Billion KRW | 4.51% |
| 2023 Q2 | 210.48 Billion KRW | 1.49% |
| 2023 FY | 226.6 Billion KRW | 11.58% |
| 2023 Q4 | 226.6 Billion KRW | 3.01% |
| 2022 Q1 | 203.16 Billion KRW | 4.67% |
| 2022 Q2 | 203.96 Billion KRW | 0.39% |
| 2022 Q3 | 203.87 Billion KRW | -0.04% |
| 2022 Q4 | 203.08 Billion KRW | -0.39% |
| 2022 FY | 203.08 Billion KRW | 4.63% |
| 2021 FY | 194.09 Billion KRW | 3.19% |
| 2021 Q1 | 192.12 Billion KRW | 2.14% |
| 2021 Q2 | 190.18 Billion KRW | -1.01% |
| 2021 Q3 | 185.04 Billion KRW | -2.7% |
| 2021 Q4 | 194.09 Billion KRW | 4.89% |
| 2020 Q3 | 200.39 Billion KRW | -0.93% |
| 2020 Q2 | 202.28 Billion KRW | -0.24% |
| 2020 Q1 | 202.76 Billion KRW | 1.16% |
| 2020 FY | 188.1 Billion KRW | -6.16% |
| 2020 Q4 | 188.1 Billion KRW | -6.13% |
| 2019 Q2 | 210.61 Billion KRW | 4.34% |
| 2019 Q3 | 196.97 Billion KRW | -6.48% |
| 2019 Q4 | 200.44 Billion KRW | 1.76% |
| 2019 FY | 200.44 Billion KRW | 2.21% |
| 2019 Q1 | 201.85 Billion KRW | 2.93% |
| 2018 Q2 | 195.85 Billion KRW | -1.87% |
| 2018 Q4 | 196.11 Billion KRW | -1.23% |
| 2018 FY | 196.11 Billion KRW | -3.79% |
| 2018 Q1 | 199.59 Billion KRW | -2.08% |
| 2018 Q3 | 198.55 Billion KRW | 1.37% |
| 2017 Q3 | 205.97 Billion KRW | -2.23% |
| 2017 Q4 | 203.84 Billion KRW | -1.03% |
| 2017 FY | 203.84 Billion KRW | 2.25% |
| 2017 Q1 | 207.41 Billion KRW | 4.04% |
| 2017 Q2 | 210.67 Billion KRW | 1.57% |
| 2016 Q4 | 199.35 Billion KRW | 0.35% |
| 2016 FY | 199.35 Billion KRW | 2.92% |
| 2016 Q3 | 198.65 Billion KRW | 2.6% |
| 2016 Q2 | 193.63 Billion KRW | 0.58% |
| 2016 Q1 | 192.51 Billion KRW | -0.61% |
| 2015 Q2 | 188.42 Billion KRW | 3.08% |
| 2015 Q4 | 193.69 Billion KRW | 1.39% |
| 2015 Q3 | 191.04 Billion KRW | 1.39% |
| 2015 Q1 | 182.79 Billion KRW | 2.14% |
| 2015 FY | 193.69 Billion KRW | 8.23% |
| 2014 Q1 | 164.89 Billion KRW | -2.62% |
| 2014 Q2 | 164.56 Billion KRW | -0.2% |
| 2014 FY | 178.96 Billion KRW | 5.69% |
| 2014 Q4 | 178.96 Billion KRW | 4.19% |
| 2014 Q3 | 171.77 Billion KRW | 4.38% |
| 2013 Q3 | 175.25 Billion KRW | 0.81% |
| 2013 Q4 | 169.33 Billion KRW | -3.38% |
| 2013 Q2 | 173.84 Billion KRW | 5.35% |
| 2013 FY | 169.33 Billion KRW | 4.56% |
| 2013 Q1 | 165.02 Billion KRW | 1.9% |
| 2012 FY | 161.95 Billion KRW | 2.64% |
| 2012 Q4 | 161.95 Billion KRW | -0.9% |
| 2012 Q3 | 163.41 Billion KRW | 4.93% |
| 2012 Q2 | 155.73 Billion KRW | 0.8% |
| 2012 Q1 | 154.49 Billion KRW | -2.09% |
| 2011 FY | 157.78 Billion KRW | 6.77% |
| 2011 Q2 | 145.7 Billion KRW | 1.45% |
| 2011 Q1 | 143.61 Billion KRW | -2.82% |
| 2011 Q4 | 157.78 Billion KRW | 7.81% |
| 2011 Q3 | 146.35 Billion KRW | 0.45% |
| 2010 Q1 | 137.39 Billion KRW | 0.01% |
| 2010 Q4 | 147.78 Billion KRW | -2.69% |
| 2010 Q3 | 151.85 Billion KRW | 12.67% |
| 2010 Q2 | 134.77 Billion KRW | -1.91% |
| 2010 FY | 147.78 Billion KRW | 7.57% |
| 2009 Q1 | 140.13 Billion KRW | 6.22% |
| 2009 Q4 | 137.38 Billion KRW | 3.2% |
| 2009 FY | 137.38 Billion KRW | 4.13% |
| 2009 Q2 | 134.47 Billion KRW | -4.04% |
| 2009 Q3 | 133.12 Billion KRW | -1.01% |
| 2008 Q2 | 107.24 Billion KRW | -0.48% |
| 2008 Q4 | 131.93 Billion KRW | 22.89% |
| 2008 FY | 131.93 Billion KRW | 22.04% |
| 2008 Q3 | 107.36 Billion KRW | 0.11% |
| 2008 Q1 | 107.75 Billion KRW | -0.33% |
| 2007 Q1 | 134.86 Billion KRW | 0.0% |
| 2007 Q4 | 108.11 Billion KRW | -4.44% |
| 2007 Q3 | 113.13 Billion KRW | -1.7% |
| 2007 Q2 | 115.09 Billion KRW | -14.66% |
| 2007 FY | 108.11 Billion KRW | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -14.322% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 88.422% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | 74.162% |
| HANDOK Inc. | 790.33 Billion KRW | 71.329% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | -32.81% |
| Yuhan Corporation | 2814.07 Billion KRW | 91.948% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | 82.771% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -142.408% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 88.392% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | 5.483% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 51.674% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -97.09% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | 4.205% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | 34.957% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -14.322% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | 45.943% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | 54.659% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | 61.554% |
| JW Holdings Corporation | 1176.26 Billion KRW | 80.736% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | 62.929% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | 83.842% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 64.87% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | 35.272% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -47.104% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | 38.869% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | 53.501% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -14.322% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | 78.981% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 87.2% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 64.87% |
| Yuhan Corporation | 2814.07 Billion KRW | 91.948% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | 74.25% |
| Suheung Co., Ltd. | 993.73 Billion KRW | 77.197% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 64.87% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | 46.035% |
| Korea United Pharm Inc. | 468.86 Billion KRW | 51.67% |
| CKD Bio Corp. | 293.78 Billion KRW | 22.869% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | 55.393% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | 59.892% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | 43.523% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | 35.272% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 84.437% |
| Boryung Corporation | 922.36 Billion KRW | 75.433% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | 48.786% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 51.674% |
| JW Lifescience Corporation | 255.83 Billion KRW | 11.427% |